Abstract：
The success of allogeneic hematopoietic stem cell transplantation is dependent on a world-wide network of collection centers providing donations that predominantly have been infused as fresh cells. The logistics chain that supports the just-in-time delivery model for stem cell and immunotherapy products was severely stressed by the COVID pandemic, and in early 2020 a number of national and international bodies recommended that cells should be cryopreserved at the collection or transplant center to avoid interruptions in their acquisition or delivery to patients who had started conditioning.
To assess the potential consequences of such pandemic-related deviations to normal practice, we surveyed nine international laboratories to determine if the characteristics or transplant outcomes of allogeneic stem cell donations differed in the immediate periods before and after the switch to routine cryopreservation.
Nine centers on two continents provided data for 72 HSC donations just before, and 71 just after, switching to cryopreservation for allogeneic HSC products. No statistically significant differences between the period before and after cryopreservation were noted for time from product collection to receipt, product temperature at receipt, or CD34+ cell viability at receipt. There was an indication of slower absolute neutrophil count recovery after cryopreservation was required (mean time of 15 vs. 17.6 days).
While there were no apparent changes to most parameters studied, there was an indication of slower neutrophil engraftment that will need to be examined in larger, longer term studies.
To assess the potential consequences of such pandemic-related deviations to normal practice, we surveyed nine international laboratories to determine if the characteristics or transplant outcomes of allogeneic stem cell donations differed in the immediate periods before and after the switch to routine cryopreservation.
Nine centers on two continents provided data for 72 HSC donations just before, and 71 just after, switching to cryopreservation for allogeneic HSC products. No statistically significant differences between the period before and after cryopreservation were noted for time from product collection to receipt, product temperature at receipt, or CD34+ cell viability at receipt. There was an indication of slower absolute neutrophil count recovery after cryopreservation was required (mean time of 15 vs. 17.6 days).
While there were no apparent changes to most parameters studied, there was an indication of slower neutrophil engraftment that will need to be examined in larger, longer term studies.
摘要：
背景：异基因造血干细胞移植的成功取决于世界范围的收集中心网络，这些中心提供的捐赠主要是作为新鲜细胞输注的。支持干细胞和免疫治疗产品准时交货模式的物流链受到COVID大流行的严重压力，在2020年初，许多国家和国际机构建议应在收集或移植中心冷冻保存细胞，以避免中断对开始调理的患者的获取或交付。
方法：为了评估这种与大流行相关的偏差对正常实践的潜在后果，我们调查了9个国际实验室,以确定异基因干细胞捐献的特征或移植结局在转换为常规冷冻保存前后的近期是否不同.
结果：两大洲的九个中心提供了之前72例HSC捐赠的数据，就在71号之后，转换为同种异体HSC产品的冷冻保存。从产品收集到接收的时间，在冷冻保存之前和之后的时间之间没有统计学上的显着差异，产品温度在收据，或收到时的CD34+细胞活力。需要冷冻保存后，有迹象表明中性粒细胞绝对计数恢复较慢（平均时间为15vs.17.6天）。
结论：虽然研究的大多数参数没有明显变化，有一个迹象表明，较慢的中性粒细胞植入，将需要在较大的检查，长期研究。
方法：为了评估这种与大流行相关的偏差对正常实践的潜在后果，我们调查了9个国际实验室,以确定异基因干细胞捐献的特征或移植结局在转换为常规冷冻保存前后的近期是否不同.
结果：两大洲的九个中心提供了之前72例HSC捐赠的数据，就在71号之后，转换为同种异体HSC产品的冷冻保存。从产品收集到接收的时间，在冷冻保存之前和之后的时间之间没有统计学上的显着差异，产品温度在收据，或收到时的CD34+细胞活力。需要冷冻保存后，有迹象表明中性粒细胞绝对计数恢复较慢（平均时间为15vs.17.6天）。
结论：虽然研究的大多数参数没有明显变化，有一个迹象表明，较慢的中性粒细胞植入，将需要在较大的检查，长期研究。
